Table 3.
Changes in outcome parameters after 24 weeks treatment
| Variable |
The group A (n = 29) |
The group B (n = 27) |
||
|---|---|---|---|---|
| Baseline | 24 weeks | Baseline | 24 weeks | |
| Triglyceride (mmol/L) |
3.26 ± 1.14 |
3.16 ± 1.12 |
3.28 ± 1.16 |
3.24 ± 1.15 |
| Total Cholesterol (mmol/L) |
6.23 ± 1.41 |
6.18 ± 1.72 |
6.19 ± 1.51 |
6.17 ± 1.68 |
| HDL-Cholesterol (mmol/L) |
1.04 ± 0.23 |
1.14 ± 0.38 |
1.12 ± 0.21 |
1.13 ± 0.24 |
| LDL-Cholesterol (mmol/L) |
4.13 ± 1.01 |
3.67 ± 1.12 |
4.20 ± 1.02 |
3.81 ± 1.20 |
| Serum C peptide (ng/ml) |
1.06 ± 0.68 |
1.18 ± 0.66 |
1.06 ± 0.70 |
1.10 ± 0.69 |
| HMW adiponectin (ug/ml) | 3.12 ± 1.56 | 5.86 ± 1.62* | 3.22 ± 1.54 | 3.24 ± 1.53## |
Data expressed mean ± SD; LDL: low-density lipoprotein; HMW: high-molecular weight; *p < 0.05 difference compared with baseline, ##p < 0.01 compared absolute changes between the group A and group B following 24 weeks glimepiride treatment.